|Mr. Nick Leschly||Pres & Director||841.95k||N/A||1973|
|Mr. William D. Baird III||Principal Financial & Accounting Officer||718.61k||N/A||1972|
|Mr. Andrew Obenshain||CEO & Director||N/A||N/A||1974|
|Ms. Gina R. Consylman CPA||Chief Financial Officer||N/A||N/A||1973|
|Mr. Kasra Kasraian||Sr. VP of Technical Devel. & Operations||N/A||N/A||N/A|
|Ms. Jessica Whitten||Chief Accounting Officer & Principal Accounting Officer||N/A||N/A||1976|
|Ms. Ingrid Goldberg||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Helen C. Fu||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||N/A|
|Ms. Elizabeth Pingpank||Director of Corp. Communications||N/A||N/A||N/A|
|Sarah Alspach||Chief Communications Officer||N/A||N/A||N/A|
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent Ã-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 6; Compensation: 8.